AWM
PCVX icon

Avior Wealth Management’s Vaxcyte PCVX Stock Holding History

Avior Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Sell
5,744
-2,903
-34% -$158K 0.01% 629
2026
Q1 		$502K Sell
8,647
-840
-9% -$45.6K 0.01% 533
2025
Q4 		$438K Sell
9,487
-1,544
-14% -$69.1K 0.01% 500
2025
Q3 		$397K Buy
11,031
+2,502
+29% +$82.9K 0.01% 510
2025
Q2 		$277K Buy
8,529
+1,730
+25% +$56.7K 0.01% 589
2025
Q1 		$257K Buy
6,799
+343
+5% +$27.4K 0.01% 590
2024
Q4 		$528K Buy
6,456
+1,124
+21% +$112K 0.02% 434
2024
Q3 		$609K Sell
5,332
-499
-9% -$45K 0.02% 406
2024
Q2 		$440K Buy
5,831
+1,129
+24% +$76.9K 0.02% 466
2024
Q1 		$321K Buy
4,702
+32
+0.7% +$2.22K 0.01% 561
2023
Q4 		$293K Buy
4,670
+1,183
+34% +$61.4K 0.02% 455
2023
Q3 		$178K Buy
+3,487
New +$172K 0.01% 545

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Avior Wealth Management's PCVX Position: Q2 2026 in Review

Avior Wealth Management reduced its Vaxcyte (PCVX) stake by 34% in Q2 2026, selling an estimated $158K and leaving 5,744 shares worth $334K. The position accounts for 0.01% of the portfolio, ranked #629.

Avior Wealth Management first reported a position in PCVX in Q3 2023 and has held it in 12 quarters since. The position peaked at $609K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Avior Wealth Management held 5,744 shares of Vaxcyte worth $334K as of Q2 2026.
  • Avior Wealth Management sold 2,903 Vaxcyte shares in Q2 2026, an estimated $158K.
  • Vaxcyte made up 0.01% of Avior Wealth Management's portfolio in Q2 2026, its #629 holding.
  • Avior Wealth Management first reported a position in Vaxcyte in Q3 2023 and has held it in 12 quarters since.
  • Avior Wealth Management's Vaxcyte position peaked at $609K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Avior Wealth Management's 13F filing for Q2 2026, filed 7 Jul 2026.